Fifth, our model does not incorporate elevated mortality
risks from non-HCV causes among people with
HCV but without past injection-drug use. Recent research
indicates that excess mortality among these individuals for
both hepatic and nonhepatic causes may be substantial,
and this limitation probably led to a more favorable ICER
(66).